A股，密集公告！脑机接口，突传重磅！

Core Viewpoint - The article highlights the rapid growth and investment activity in the brain-computer interface (BCI) sector, particularly focusing on the recent significant financing of Qiangnao Technology, which has raised approximately 2 billion yuan, marking it as the second-largest financing in the BCI field globally after Neuralink [2][3]. Investment Landscape - The BCI sector has emerged as a hot investment area in the A-share market since the beginning of 2026, with multiple stocks such as Innovation Medical, Aipeng Medical, and Xiangyu Medical experiencing consecutive trading gains [2]. - Qiangnao Technology, part of the "Hangzhou Six Little Dragons," has attracted a strong lineup of investors, including IDG and major tech firms, and has received FDA and CE certifications for its products [3][4]. Company Developments - Qiangnao Technology, founded in 2015, focuses on non-invasive BCI technology and has launched several products, including smart bionic limbs and brain-machine sleep aids [3]. - The company has a history of significant funding rounds, including a $400 million Series A round in 2019 and subsequent rounds totaling $30 million and $20 million in 2025 [4]. Market Dynamics - The BCI industry is currently experiencing a dual boost from policy support and technological breakthroughs, with expectations for Neuralink to begin large-scale production of BCI devices in 2026 [4]. - Companies like Sanbo Brain Science, Meilan De, and Xiangyu Medical have issued announcements regarding stock trading volatility, indicating the heightened interest and speculative nature of the market [5][6]. Product and Technology Focus - Xiangyu Medical is concentrating on non-invasive BCI technology and has made significant investments in R&D, with over 60% of its R&D budget directed towards BCI-related projects [7]. - The company aims to integrate BCI technology with its rehabilitation equipment, targeting to cover over 1,000 top-tier hospitals by 2026 [7].